Policy & Regulation
AstraZeneca's Enhertu recommended for EU approval in HER2-positive solid tumours
...
Lundbeck's Vyepti (eptinezumab) receives South Korean approval for preventive treatment of migraine
26 May 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH:HLUN-A) announced on Tuesday that the Ministry of Food and Drug Safety (MFDS) of South Korea has granted marketing authorisation for...
Eli Lilly reports positive Phase 1b results for VERVE-102
26 May 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) on Monday reported positive Phase 1b Heart-2 study results for VERVE-102, an investigational in vivo base editing medicine desi...
Pierre Fabre Laboratories' BRAFTOVI (encorafenib) combination receives CHMP positive opinion in BRAFV600E-mutant mCRC
26 May 2026 - French pharmaceutical company Pierre Fabre Laboratories announced on Monday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issu...
Menarini Group to present new elacestrant and tagraxofusp data at ASCO 2026 Annual Meeting
26 May 2026 - Italian pharmaceutical and diagnostics company the Menarini Group and its subsidiary Stemline Therapeutics Inc announced on Monday that new data related to elacestrant and tagraxofusp wi...
Hansa Biopharma's ConfIdeS Phase 3 trial abstract selected for ATC 2026
26 May 2026 - Swedish biopharmaceutical company Hansa Biopharma AB (STO:HNSA) announced on Monday that results from its US Phase 3 ConfIdeS trial in kidney transplantation have been accepted and selec...